PDF Número - Revista Española Endocrinología Pediátrica

Recommendations

Info

MESA REDONDA CONSIDERACIONES ACTUALES DE LA VITAMINA D Vitamin D and Adiposity Studies in adults and children have shown a link between obesity and vitamin D status. Serum 25-hydroxyvitamin D [25(OH)D], the recognized biomarker of vitamin D status, is inversely associated with clinical and laboratory measures of adiposity such as body mass index (BMI), waist circumference and percentage body fat in adults and youth. Our research aimed to specifically examine the relationship between vitamin D status and abdominal adiposity, and lipids in children, and the impact of race (black vs. white) since body fat topography and lipid profile differ between black and white youth. Plasma 25(OH)D, adiposity [body mass index (BMI), percentage of total body fat, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)], and fasting lipids were assessed in healthy obese and nonobese 8- to 18-yr-old black and white children. We studied 237 children (mean ± SD age, 12.7 ± 2.2 yr; 47% black, 47% obese, and 43% male). Mean 25(OH)D concentration for the entire cohort was 19.4 ± 7.4 ng/ml. The majority of the children, 73% of blacks and 40% of whites, were vitamin D deficient [25(OH)D < 20 ng/ml]. Plasma 25(OH)D was associated inversely with BMI, BMI percentile, percentage of total body fat, VAT, and SAT and positively with HDL cholesterol in the entire cohort. VAT was higher in vitamin D-deficient whites, and SAT was higher in vitamin D-deficient blacks compared with their respective vitamin D-nondeficient counterparts. In conclusion, vitamin D deficiency and insufficiency are highly prevalent in 8-18 year old preadolescents and adolescent children residing in the Northeast United States. Lower levels of 25(OH)D are asso- Rev Esp Endocrinol Pediatr 2012; 3 (Suppl) doi: 10.3266/RevEspEndocrinolPediatr.pre2012.Apr.121 Vitamin D, adiposity, insulin sensitivity and beta cell function in children Silva Arslanian. Weight Management & Wellness Center, Children’s Hospital of Pittsburgh of UPMC, USA. ciated with higher adiposity measures and lower HDL. Race, female gender, season, pubertal status and visceral adiposity are independent predictors of plasma 25(OH)D status. Besides therapeutic interventions to correct the high rates of vitamin D deficiency in youth, benefits of vitamin D optimization on adiposity measures and lipid profile need to be explored. Vitamin D and In Vivo Insulin Sensitivity and β-Cell Function Vitamin D is proposed to play a role in glucose homeostasis and b-cell function. In adults, low 25(OH) D concentration is found to be associated with higher risk of hyperglycemia, insulin resistance and type 2 diabetes. Data are limited in children. Therefore, we aimed to assess the relationships between plasma 25(OH)D and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity, the disposition index (DI), in youth. Plasma 25(OH)D concentrations were analyzed in healthy youth aged 8 to 18 years who had undergone hyperinsulinemic-euglycemic and hyperglycemic clamp evaluations to measure insulin sensitivity and secretion. In addition body composition and body fat topography was evaluated for abdominal visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). A total of 183 research volunteers (mean ± SD; age, 12.6 ± 2.2 years; 98 white, 98 male, 92 obese) were studied. Analysis of HbA 1c , fasting glucose and insulin, insulin sensitivity, and b-cell function across quartiles of plasma 25(OH)D revealed no differences among whites. In blacks, the observed significance of higher insulin sensitivity and DI in the highest quartile of 25(OH)D disappeared after 49
adjusting for any of the adiposity measures (BMI or fat mass or VAT or SAT). The difference in insulin sensitivity (9.4 ± 1.2 vs. 5.6 ± 0.5 mg/kg/min per μU/mL; P = 0.006) between 25(OH)D nondeficient (≥20 ng/mL) versus deficient (
Page 2: Presidente Juan Pedro López Siguer
Page 6 and 7: Proceedings of Spanish Pediatric En
Page 8 and 9: CONFERENCIAS Saber para prevenir. C
Page 10: Es necesario, a estos efectos, tene
Page 13 and 14: Contribuciones importantes al conoc
Page 15 and 16: ellos emparentados 36 . La demostra
Page 17 and 18: 35. Phillips III JA, Hjelle BL, See
Page 19 and 20: Mutación KCNJ11 ABCC8 INS heterozi
Page 21 and 22: 6º mes de edad. La herencia es AD
Page 23 and 24: 4. Gloyn AL, Reimann F, Girard C, E
Page 26 and 27: MESA REDONDA Rev Esp Endocrinol Ped
Page 28 and 29: Análisis molecular del eje GH/IGF-
Page 34 and 35: MESA REDONDA Rev Esp Endocrinol Ped
Page 36 and 37: Expresión y contenido placentario
Page 38: Expresión y contenido placentario
Page 41 and 42: Tabla 1. Contenido de vitamina D se
Page 43 and 44: Figura 6. Osteoporosis Internaciona
Page 45 and 46: 2. Bikle DD. Vitamin D regulation o
Page 48 and 49: MESA REDONDA CONSIDERACIONES ACTUAL
Page 52 and 53: ENCUENTRO CON EL EXPERTO Importanci
Page 54 and 55: Importancia del yodo en la nutrici
Page 56 and 57: ENCUENTRO CON EL EXPERTO Introducci
Page 58 and 59: Controversias: Utilidad del tratami
Page 60 and 61: Controversias: Utilidad del tratami
Page 62 and 63: ENCUENTRO CON EL EXPERTO La hiperpl
Page 64 and 65: Hiperplasia suprarrenal congénita
Page 74: Hiperplasia suprarrenal congénita
Page 77 and 78: superior con extensión progresiva
Page 79 and 80: diagnóstico de deleciones o duplic
Page 81 and 82: 22. Van der Graaf A, Avis HJ, Kuste
Page 83 and 84: de glucemia que conlleven una actua
Page 85 and 86: científica creciente lleve a un ca
Page 87 and 88: Tabla 2. Objetivos glucémicos en l
Page 89 and 90: mg/dL, la sensibilidad para la dete
Page 92 and 93: COMUNICACIONES COMUNICACIONES ORALE
Page 94 and 95: media) y marcadores analíticos de
Page 96 and 97: ación en el crecimiento comienza p
Page 98 and 99: F.J. Caballero Mora, G. Ángel Mart
Page 100 and 101:
entre 8-17 años y a una población
Page 102 and 103:
Miscelánea O2d2-016 PATOLOGÍA END
Page 104 and 105:
elacionados y otros genes que codif
Page 106 and 107:
(1) Hospital Parc de Salut Mar, Bar
Page 108 and 109:
fectos de TSHB y TRHR, y en diferen
Page 110 and 111:
A: Sin alteración RI AGA IHC Signi
Page 112:
proteínas de baja densidad (c-LDL)
Page 115 and 116:
en jóvenes. Se desconoce si existe
Page 117 and 118:
Resultados: Los niveles de expresi
Page 119 and 120:
nución en la masa beta y en el nú
Page 121 and 122:
nen en alerta del riesgo que corren
Page 123 and 124:
Material y métodos: Revisión de i
Page 125 and 126:
Conclusiones: El 10,7% de los pacie
Page 127 and 128:
DE (10,5 cm). Además 7 presentaban
Page 129 and 130:
Son escasas las casuísticas que va
Page 131 and 132:
espiratoria alta por VRS, presenta
Page 133 and 134:
nos. A la exploración no se observ
Page 135 and 136:
en niños. Aunque se desconocen los
Page 137 and 138:
desarrollo mamario, menarquia, y me
Page 139 and 140:
A. Clavijo Pendón, A. P. Naso Roca
Page 141 and 142:
3horas: FSH: 86,6 mUI/ml, LH: 28,3
Page 143 and 144:
L. Losada Burbano, L. Velazquez, M.
Page 145 and 146:
es difícil de recuperar. Parece qu
Page 147 and 148:
plasias o histicocitosis), traumati
Page 149 and 150:
P1d2d3-038 FENOTIPOS ASOCIADOS A MU
Page 151 and 152:
El PPHP es un trastorno genético p
Page 153 and 154:
Conclusiones: Las distintas alterac
Page 155 and 156:
tratamiento con alendronato oral 10
Page 157 and 158:
Objetivo: Presentación de un caso
Page 159 and 160:
diaxózido e hidroclorotiazida. Glu
Page 161 and 162:
hipoglucemia sintomática junto con
Page 163 and 164:
P1d2d3-063 DIABETES NEONATAL PERMAN
Page 165 and 166:
familiar de DM tipo 2 y DM tipo 1 a
Page 167 and 168:
Introducción: La presencia de rese
Page 169 and 170:
y 65,5% análogos de acción rápid
Page 171 and 172:
Introducción: La composición quí
Page 173 and 174:
han probado múltiples tratamientos
Page 175 and 176:
(Kiddo-Kindl). Además incluye dos
Page 177 and 178:
P1d2d3-088 FACTORES PREDISPONENTES
Page 179 and 180:
necesario implementar programas efe
Page 181 and 182:
Conclusión: El sobrepeso y la obes
Page 183 and 184:
La obesidad infantil. Problema soci
Page 185 and 186:
los 3 años. La principal limitaci
Page 187 and 188:
nes analíticas y óseas. Anteceden
Page 189 and 190:
Pruebas complementarias: Hemoglobin
Page 191 and 192:
idades en la evolución de cada una
Page 193 and 194:
niveles de TSH, T4L, anticuerpos an
Page 195 and 196:
TA. Se realizó un estudio descript
Page 197 and 198:
vención. Se confirma el diagnósti
Page 199 and 200:
con levotiroxina sódica por hallaz
Page 201 and 202:
tratamiento de la esteatosis recibe
Page 203 and 204:
Introducción: En 2003 la Agencia E
Page 205 and 206:
Biosimilar Biosintética Inicio Al
Page 207 and 208:
gen GH1: polimorfismo P1 en heteroc
Page 209 and 210:
Teruel. (5) Hospital Infantil Unive
Page 212 and 213:
ÍNDICE DE AUTORES Autores A Abadal
Page 214 and 215:
Índice de Autores D De la Cruz Mor
Page 216 and 217:
Índice de Autores Iglesias Álvare
Page 218 and 219:
Índice de Autores Perales Martíne
Page 220:
Índice de Autores Villalba, C. Vil
show all

PDF Número - Revista Española Endocrinología Pediátrica

Create successful ePaper yourself

Delete template?

Save as template?